iNova Pharmaceuticals announces the launch of iPitch 2020

Following on from the success of the inaugural iPitch launch in 2019, iNova Pharmaceuticals is delighted to announce the launch of a new round of iPitch challenges for 2020.
iPitch is a collaborative crowdsourcing program that allows product and packaging developers, innovators, licensors and certified manufacturers to connect with iNova and share their great ideas for healthcare products that have the potential for commercialisation.
It provides a wonderful opportunity for anyone with new and different ideas or next-generation solutions that may not have the resources or expertise to bring their innovations to market, or just looking for a commercialisation partner.
According to iNova Executive Director and Head of Innovation, Filomena Maiese, “We know there’s consumer health product innovations out there that haven’t yet been commercialised. We want to partner with them.”
iPitch specifically looks for effective, evidence-based products with innovative and new formats and formulations. After creating a lot of buzz last year, and by leveraging the power of global connectivity, the 2019 iPitch received hundreds of different and diverse product and formulation ideas from around the world. iNova is currently preparing to launch two of these products into the marketplace, which otherwise would not have had a chance to make it to consumers.
Entries for iPitch can be made according to criteria set out by iNova within a range of set ‘challenges’. This year, iNova has created and carefully selected a diverse set of challenges across which submissions can be made. This provides more opportunity for innovators to submit entries and captures ideas across a wide range of consumer healthcare needs. The challenges cover products from pregnancy supplements to packaging to face masks to cough, cold and flu formulations.
iNova is excited about building a number of new mutually beneficial business partnerships through iPitch. According to Chief Executive Officer, Dan Spira, “iNova has a strong track record of acquiring, building and launching trusted consumer healthcare brands, which makes us a great partner of choice for product owners and licensors globally”.
iNova has a diverse range of market-leading products. They have a trusted reputation among consumers and healthcare professionals and are recognised as an innovative partner of choice in the healthcare industry. With a multi-national business platform, it offers access to well-established operating platforms and broad distribution networks across Asia, Africa and ANZ.
iPitch will be open for applications for 12 weeks, ending 21 August 2020.
Related News
-
News Rebuilding the United States' pharma infrastructure – CPHI North America 2023 preview
As we prepare for CPHI North America from April 25–27 in Philadelphia, USA, CPHI Online caught up with some of the track sponsors to discuss how the show connects vital players within the North American pharmaceutical landscape. ... -
News Digital-first experimental approach to optimise drug formulations
Merck and XtalPi Inc. collaborate on an AI-powered technology platform to predict the crystal morphologies of diabetic medication metformin HCl, validated by wet-lab experiments conducted with Merck’s expertise, in a ‘digital-first’ a... -
News To recruit or to retain - where is the pharma talent going?
Discover how the pharmaceutical workforce has evolved past the pandemic, and the challenges faced by the pharma industry during a talent acquisition and retention crisis. -
News NextPharma acquisition of chewable tablet manufacturing site from Takeda complete
NextPharma has completed their acquisition of a Norway-based manufacturing site, specialising in chewable tablet technologies for calcium/vitamin D3 from pharmaceutical giant Takeda. -
News Doctors Without Borders demands transparency from GSK on licensing agreements for preventative HIV treatment
GSK has signed licensed agreements with three companies to manufacture generic versions of its preventative HIV medicine for distribution in lower-income countries but calls for increased transparency is putting pressure on the drugmaker. -
News Thermo Fisher Scientific and UCSF open cell therapy manufacturing facility
In collaboration with Thermo Fisher Scientific, UCSF has opened a new manufacturing site aimed at accelerating advanced cell and gene therapies for cancer, rare diseases, and other illnesses. -
News 3 ways ChatGPT will impact pharma marketing teams
What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers? -
News Innovation in Drug Delivery & Portfolio Renovation with Sofgen Pharmaceuticals
The Pharma industry is expected to reach $1.9Tn in revenue by 2027, increasing at a rate of 3-6% per year, according to IQVIA1, with some regions being driven by volume, and others by innovation. Growth in developed economies is projected to be slow, w...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance